Neuren Pharmaceuticals Future Growth
Future criteria checks 2/6
Neuren Pharmaceuticals is forecast to grow earnings and revenue by 4.6% and 3.1% per annum respectively. EPS is expected to grow by 4.9% per annum. Return on equity is forecast to be 24.2% in 3 years.
Key information
4.6%
Earnings growth rate
4.9%
EPS growth rate
Pharmaceuticals earnings growth | 19.6% |
Revenue growth rate | 3.1% |
Future return on equity | 24.2% |
Analyst coverage | Good |
Last updated | 09 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 187 | 118 | 100 | 80 | 5 |
12/31/2025 | 160 | 104 | 123 | 114 | 6 |
12/31/2024 | 123 | 80 | -28 | 37 | 6 |
6/30/2024 | 193 | 117 | 119 | 120 | N/A |
3/31/2024 | 213 | 137 | 152 | 152 | N/A |
12/31/2023 | 232 | 157 | 185 | 185 | N/A |
9/30/2023 | 155 | 106 | 120 | 120 | N/A |
6/30/2023 | 78 | 55 | 54 | 54 | N/A |
3/31/2023 | 47 | 28 | 29 | 29 | N/A |
12/31/2022 | 15 | 0 | 4 | 4 | N/A |
9/30/2022 | 9 | -3 | -3 | -3 | N/A |
6/30/2022 | 3 | -7 | -10 | -10 | N/A |
3/31/2022 | 3 | -7 | -10 | -10 | N/A |
12/31/2021 | 3 | -8 | -10 | -10 | N/A |
9/30/2021 | 2 | -10 | -10 | -10 | N/A |
6/30/2021 | 1 | -12 | -9 | -9 | N/A |
3/31/2021 | 1 | -11 | -9 | -9 | N/A |
12/31/2020 | 1 | -9 | -8 | -8 | N/A |
9/30/2020 | 1 | -8 | -9 | -9 | N/A |
6/30/2020 | 0 | -8 | -9 | -9 | N/A |
3/31/2020 | 0 | -9 | -10 | -10 | N/A |
12/31/2019 | 0 | -11 | -12 | -12 | N/A |
9/30/2019 | 7 | -6 | -5 | -5 | N/A |
6/30/2019 | 14 | -1 | 2 | 2 | N/A |
3/31/2019 | 14 | 1 | 4 | 4 | N/A |
12/31/2018 | 14 | 3 | 6 | 6 | N/A |
9/30/2018 | 7 | 3 | 0 | 0 | N/A |
6/30/2018 | 1 | 3 | -6 | -6 | N/A |
3/31/2018 | 1 | 3 | N/A | -6 | N/A |
12/31/2017 | 1 | 3 | N/A | -6 | N/A |
9/30/2017 | 2 | -2 | N/A | -7 | N/A |
6/30/2017 | 3 | -8 | N/A | -8 | N/A |
3/31/2017 | 3 | -10 | N/A | -10 | N/A |
12/31/2016 | 3 | -12 | N/A | -12 | N/A |
9/30/2016 | 2 | -14 | N/A | -14 | N/A |
6/30/2016 | 0 | -15 | N/A | -17 | N/A |
3/31/2016 | 1 | -14 | N/A | -15 | N/A |
12/31/2015 | 2 | -13 | N/A | -13 | N/A |
9/30/2015 | 2 | -11 | N/A | -11 | N/A |
6/30/2015 | 3 | -9 | N/A | -8 | N/A |
3/31/2015 | 3 | -9 | N/A | -7 | N/A |
12/31/2014 | 3 | -8 | N/A | -6 | N/A |
9/30/2014 | 3 | -10 | N/A | -7 | N/A |
6/30/2014 | 3 | -12 | N/A | -7 | N/A |
3/31/2014 | 4 | -11 | N/A | -7 | N/A |
12/31/2013 | 5 | -10 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NK9's forecast earnings growth (4.6% per year) is above the savings rate (0.8%).
Earnings vs Market: NK9's earnings (4.6% per year) are forecast to grow slower than the German market (20% per year).
High Growth Earnings: NK9's earnings are forecast to grow, but not significantly.
Revenue vs Market: NK9's revenue (3.1% per year) is forecast to grow slower than the German market (5.4% per year).
High Growth Revenue: NK9's revenue (3.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NK9's Return on Equity is forecast to be high in 3 years time (24.2%)